share_log

Leerink Partners Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $44

Benzinga ·  Nov 19 23:44  · Ratings

Leerink Partners analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $46 to $44.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment